

The drug use-results survey (All-Case Surveillance) on Prizbind® for Intravenous Solution 2.5 g in Japan (PMS for idarucizumab)

First published: 27/10/2016

Last updated: 18/12/2025

Study

Finalised

Administrative details

EU PAS number

EUPAS15981

Study ID

48788

DARWIN EU® study

No

Study countries

 Japan

Study description

Study to evaluate safety and effectiveness of Prizbind® for Intravenous Solution
2.5 g under Japanese clinical condition

Study status

Finalised

Research institutions and networks

Institutions

Boehringer Ingelheim

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Multiple centres: 300 centres are involved in the
study

Contact details

Study institution contact

Yukako Ogi zzCDMJ_PV_PMS@boehringer-ingelheim.com

Study contact

zzCDMJ_PV_PMS@boehringer-ingelheim.com

Primary lead investigator

Yukako Ogi

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 25/08/2016

Actual: 19/08/2016

Study start date

Planned: 27/10/2016

Actual: 25/11/2016

Data analysis start date

Planned: 01/11/2016

Actual: 25/11/2016

Date of interim report, if expected

Planned: 03/11/2021

Actual: 24/09/2021

Date of final study report

Planned: 31/07/2022

Actual: 17/08/2022

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Nippon Boehringer Ingelheim Co., Ltd.

Study protocol

[1321-0015_protocol_redacted.pdf](#) (246.3 KB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Non-EU RMP only

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Effectiveness study (incl. comparative)

Safety study (incl. comparative)

Data collection methods:

Primary data collection

Study design:

Non-interventional study based on newly collected data

Main study objective:

Study to to evaluate safety and effectiveness of Prizbind® for Intravenous Solution 2.5 g under Japanese clinical condition

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Medicinal product name, other

Prizbind® for Intravenous Solution 2.5 g

Study drug International non-proprietary name (INN) or common name

IDARUCIZUMAB

Anatomical Therapeutic Chemical (ATC) code

(V03AB37) idarucizumab

idarucizumab

Medical condition to be studied

Upper gastrointestinal haemorrhage

Population studied

Short description of the study population

Japanese subjects with upper gastrointestinal haemorrhage treated with Prizbind (Intravenous Solution 2.5 g) under clinical condition.

Age groups

- Adults (18 to < 46 years)
 - Adults (46 to < 65 years)
 - Adults (65 to < 75 years)
 - Adults (75 to < 85 years)
 - Adults (85 years and over)
-

Estimated number of subjects

300

Study design details

Outcomes

Any suspected ADRs (primary outcome), Serious AEs, and AEs for important potential risks(hypersensitivity, thrombotic event), Reversal of anticoagulation

as measured by coagulation test

Data analysis plan

Analyses are descriptive in nature including means, standard deviation, min, Q1, medians, Q3, max, frequency and percentages

Documents

Study results

[1321-0015_Synopsis.pdf](#) (229.15 KB)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s), other

Case Report Forms (CRFs) for individual patients were provided by the sponsor

Data sources (types)

[Other](#)

Data sources (types), other

Prospective patient-based data collection

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No